25 November 2023 in Biomedicine & Pharmacotherapy
CGCristina García-Caballero
Cristina García-Caballero
GCGina Marcela Córdoba-David
Gina Marcela Córdoba-David
APAlejandra Palomino-Antolín
Alejandra Palomino-Antolín
+5
Rhabdomyolysis is a severe clinical syndrome associated to acute kidney injury (AKI) and chronic kidney disease (CKD). TWEAK/Fn14 signaling axis regulates renal inflammation and tubular cell death. However, the functional role of TWEAK/Fn14 in rhabdomyolysis remains unknown. Rhabdomyolysis was induced in wild-type, TWEAK- and Fn14-deficient mice or mice treated with TWEAK blocking antibody. Renal injury, inflammation, fibrosis and cell death were assessed. Additionally, we performed in vivo and in vitro studies to explore the possible signalling pathways involved in Fn14 regulation. Fn14 renal expression was increased in mice with rhabdomyolysis, correlating with decline of renal function. Mechanistically, myoglobin (Mb) induced Fn14 expression via ERK and p38 pathway, whereas Nrf2 activation diminished Mb-mediated Fn14 upregulation in cultured renal cells. TWEAK or Fn14 genetic depletion ameliorated rhabdomyolysis-associated loss of renal function, histological damage, tubular cell death, inflammation, and expression of both tubular and endothelial injury markers. Deficiency of TWEAK or Fn14 also decreased long-term renal inflammation and fibrosis in mice with rhabdomyolysis. Finally, pharmacological treatment with a blocking TWEAK antibody diminished the expression of acute renal injury markers and cell death and lessened residual kidney fibrosis and chronic inflammation in rhabdomyolysis. TWEAK/Fn14 axis participates in the pathogenesis of rhabdomyolysis-AKI and subsequent AKI-CKD transition. Blockade of this signaling pathway may represent a promising therapeutic strategy for reducing rhabdomyolysis-mediated renal injury. Spanish Ministry of Science and Innovation, ISCIII and Junta de Andalucía.
14 May 2026 in Biomedicine & Pharmacotherapy
Intravascular hemolysis can cause both acute kidney injury (AKI) and chronic kidney disease (CKD). When erythrocytes break down in the bloodstream, they release hemoglobin and heme derivatives, which accumulate in renal cells and lead to increased oxidative stress, inflammation, cell death, and mitochondrial dysfunction. The enzyme NADH-cytochrome b5 reductase 3 (CYB5R3) plays a role in NAD+ metabolism and helps reduce oxidative stress and inflammation while enhancing mitochondrial function. In this study, we examined whether overexpressing CYB5R3 offers kidney protection against AKI caused by intravascular hemolysis and prevents the progression from AKI to CKD, including analysis of sex-based differences. We created an experimental model to assess acute and chronic kidney damage related to intravascular hemolysis in wild-type (WT) and CYB5R3-overexpressing transgenic (TG) mice. Additionally, we performed in vitro experiments to determine if pharmacological induction of CYB5R3 with tetrahydroindenoindole (THII) reduced heme-mediated nephrotoxicity. AKI resulting from intravascular hemolysis impaired kidney function, increased damage to tubular epithelium and podocytes, promoted oxidative stress and inflammation, caused mitochondrial dysfunction, altered autophagy-related markers, and cell death-effects that were more severe in males than females. CYB5R3 overexpression notably diminished these pathological changes and slowed CKD progression by decreasing inflammation and fibrosis, regardless of sex. In cellular systems, induction of CYB5R3 with THII lowered heme-induced reactive oxygen species (ROS) production, inflammation, and cell death, and restored NAD+ levels. These protective effects were eliminated by pharmacological inhibition of CYB5R3 activity. Our findings suggest that CYB5R3 could be a promising therapeutic target for preventing AKI related to intravascular hemolysis and its progression to CKD.